Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 10773 (Empagliflozin) Monotherapy in Type 2 Diabetes
NCT00789035Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2008
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial of empagliflozin in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change of Glycosilated Haemoglobin A1c (HbA1c) From Baseline at 12 weeks. Started Oct 2008; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00789035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00789035.